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Background: Tumor-derived cytokines and their receptors usually take important roles in the disease progression
and prognosis of cancer patients. In this survey, we aimed to detect the expression levels of MIF and CXCR4 in
different cell populations of tumor microenvironments and their association with survivals of patients with
esophageal squamous cell carcinoma (ESCC).
Methods: MIF and CXCR4 levels were measured by immunochemistry in tumor specimens from 136 resected ESCC.
Correlation analyses and independent prognostic outcomes were determined using Pearson’s chi-square test and
Cox regression analysis.
Results: The expression of CXCR4 in tumor cells was positively associated with tumor status (P = 0.045) and clinical
stage (P = 0.044); whereas the expression of CXCR4 in tumor-infiltrating lymphocytes (TILs) and the expression of
MIF in tumor cells and in TILs were not associated with clinical parameters of ESCC patients. High MIF expression in
tumor cells or in TILs or high CXCR4 expression in tumor cells was significantly related to poor survival of ESCC
patients (P < 0.05). Multivariate analysis showed that the expression of MIF or CXCR4 in tumor cells and the
expression of MIF in TILs were adverse independent factors for disease-free survival (DFS) and overall survival (OS) in
the whole cohort of patients (P < 0.05). Furthermore, the expression of MIF and CXCR4 in tumor cells were
independent factors for reduced DFS and OS in metastatic/recurrent ESCC patients (P < 0.05). Interestingly, the
expressions of MIF and CXCR4 in tumor cells and in TILs were significantly positively correlated (P < 0.05), and the
combined MIF and CXCR4 expression in tumor cells was an independent adverse predictive factor for DFS and OS
(P < 0.05).
Conclusion: The expressions of MIF and CXCR4 proteins in tumor cells and TILs have different clinically predictive
values in ESCC.
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Esophageal squamous cell carcinoma (ESCC) is one of
the major histopathological subtypes of esophageal can-
cer. ESCC is the fourth most prevalent malignancy in
China and a leading cause of cancer-related death, and
its overall five-year survival rate is less than 30% [1]. It
has been reported that the molecular markers related to
tumor cell growth and metastasis, the function of the
tumor infiltrating-lymphocytes (TILs), and the inter-
action between tumor cells and infiltrated immune cells
in tumor microenvironments have been evaluated for
their contribution to the prognoses of ESCC patients in
recent studies, except the traditional prognostic factors
determined at diagnosis, such as TNM stage and cell dif-
ferentiation [2-7]. However, reliable markers for disease
development and prognosis are still lacking in ESCC. To
date, it has been revealed that the expression levels of
some over-expressed genes within tumor microenviron-
ments are related to the prognosis of ESCC, such as
interleukin 17 (IL-17), SKP2, Foxp3 and Tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL);
however the results are still conflicting [8-13].
The macrophage migration inhibitory factor (MIF) is a
115-amino acid secreted cytokine that is involved in a
number of pathological conditions, including autoimmun-
ity, obesity and cancer [14]. The primary MIF receptor is
CD74, and CD74 can bind to CD44 to form a receptor
complex and mediate the transduction of MIF signaling
[15]; However, CD74 can also form complexes with the
C-X-C chemokine receptor type 2 (CXCR2) and type 4
(CXCR4) to transmit MIF signals to integrins in inflam-
matory cells [16,17]. Recent studies have demonstrated
that MIF and CXCR4 were overexpressed in a number of
cancers, including gastric cancer, breast cancer, prostate
cancer, colon cancer and nasopharyngeal carcinoma
[18-26]. However, the expression pattern of MIF and
CXCR4 proteins in tumor microenvironments and their
impact on the survival of cancer patients are still unclear.
Therefore, we evaluated the expression of MIF and its
receptor CXCR4 protein in tumor cells and TILs of
tumor microenvironment in 136 resected ESCC speci-
mens using immunohistochmeistry staining. The corre-
lations between the expression levels of MIF and CXCR4
in different cell subsets in tumor microenvironment and
prognostic factors were assessed to determine the clin-
ical relevance and predictive value of the MIF and




One hundred and thirty-six ESCC patients who under-
went surgery at Sun Yat-Sen University Cancer Center
in Guangzhou City of China from November of 2000 toDecember of 2002 were involved in this retrospective
study. None of the patients had received anticancer
treatment prior to surgery, and all of the patients had
histologically confirmed primary ESCC. The patients
had a median age of 62 years (range, 35 to 90 years); 111
(81.6%) were males and 25 (18.4%) were females. There
were 74 (54.4%) cases of Stage I and II tumors and 62
(45.6%) cases of Stage III and IV tumors based on the
International Union against Cancer 2002 TNM staging
system and WHO classification criteria [27]. Of the 136
patients, 103 (75.7%) had died. The patients’ clinical pa-
rameters are detailed in Additional file 1: Table S1. The
tumor specimens were obtained as paraffin blocks from
the Pathology Department of our cancer center and clin-
ical data were obtained from hospital records after sur-
gery. The follow-up data from the 136 patients with
ESCC in this study were available and complete. The OS
was defined as the time interval from the date of surgery
to the date of cancer-related death or the end of follow-
up (December 2011), and the DFS was defined as the
time interval from the date of surgery to the date of
tumor recurrence or tumor metastasis. This study was
approved by the Research Ethics Committee of the Sun
Yat-Sen University Cancer Center.
Reagents and antibodies
The following primary antibodies were used in this
study: mouse anti-human MIF (ab55445; Abcam, USA),
mouse anti-human CXCR4 (Clone 44716; R&D Systems,
Minneapolis, MN), and horseradish peroxidase-labeled
goat antibody against a mouse/rabbit IgG antibody
(Envision; Dako, Glostrup, Denmark).
Immunohistochemistry and assessment
The paraffin-embedded tissues were sectioned continuously
into 4-μm-thick sections. The tissue sections were dewaxed
in xylene, rehydrated and rinsed in graded ethanol solu-
tions. The antigens were retrieved by heating the tissue sec-
tions at 100°C for 30 min in citrate (10 mmol/L, pH 6.0) or
EDTA (1 mmol/L, pH 9.0) solution when necessary. The
sections were then immersed in a 0.3% hydrogen peroxide
solution for 30 min to block endogenous peroxidase activ-
ity, rinsed in phosphate-buffered saline (PBS) for 5 min,
and incubated with the primary antibodies, including MIF,
CXCR4 at 4°C overnight. A negative control was performed
by replacing the primary antibody with a normal murine
IgG antibody. The sections were then incubated with a
horseradish peroxidase-labeled goat antibody against a
mouse/rabbit secondary antibody at room temperature for
30 min. Finally, the signal was developed for visualization
with 3, 3′-diaminobenzidine tetrahydrochloride (DAB), and
all of the slides were counterstained with hematoxylin.
Two independent observers blinded to the clinicopatho-
logical information scored the MIF and CXCR4 expression
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positively stained cells :(0, <5%; 1, 6 to 25%; 2, 26 to 50%;
3, 51 to 75%; 4, >75%) and (b) the signal intensity: (0, no
signal; 1, weak; 2, moderate; 3, strong). The score was the
product of a × b. The levels of MIF and CXCR4 expression
in lymphocytes were obtained by counting the positively
and negatively stained lymphocytes in five to ten separate
400× high-power microscopic fields and calculating the
mean percentage of positively stained lymphocytes among
the total lymphocytes per field.
Statistical analysis
All analyses were conducted with SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA). The patients were divided into two
subgroups (a high-level group and a low-level group)
based on the median values of various immunohisto-
chemical variables in our data. Pearson’s chi-square test
and Fisher’s chi-square test were used to analyze the cor-
relation between immunohistochemical variants in dif-
ferent cell subsets and the patients’ clinicopathological
parameters. The MIF and CXCR4 expression levels
were examined in tumor cells and in TILs in relation to
the patients’ clinical prognosis using the Kaplan-Meier
method and the log-rank survival analysis. Prognostic
factors were assessed by univariate and multivariate ana-
lyses using the Cox proportional hazards model. Thea c
b d
Figure 1 Immunohistochemical staining for MIF and CXCR4 in human
MIF (a) and CXCR4 (c) (X 400) and high expression levels of MIF (b) and CX
tissues from patients with ESCC. The arrows point to the positive staining orelationships among the expression levels of MIF and
CXCR4 were assessed using Pearson’s correlation coeffi-
cient and linear regression analyses. A two-tailed P-value
<0.05 was considered statistically significant in this
study.
Results
Expression patterns of MIF and CXCR4 in ESCC and their
correlations with clinicopathological and
immunohistochemical variables
In the present study, the protein expression levels of
MIF and CXCR4 were examined in tumor specimens
from 136 patients with ESCC. MIF was expressed in the
cytoplasm of tumor cells and TILs, and CXCR4 was
expressed in the nucleus or cytoplasm and cell mem-
brane of tumor cells and the cell membrane and cyto-
plasm of TILs (Figure 1). Based on the criteria described
in the Methods section, high expression levels of MIF
and CXCR4 in tumor cells were noted in samples from
73 (53.7%) and 47 (34.6%) of the 136 patients, respect-
ively. The mean percentage and the range of the per-
centage of patients with TILs positive for MIF or
CXCR4 expression per high-power light microscopic
field were 33% (range, 0 to 92%) and 20% (range, 0 to
78%), respectively, among the 136 patients assessed
(Additional file 2: Table S2).e
esophageal carcinoma. Our data showed low expression levels of
CR4 (d), compared with the negative control (e) (X 400), in tumor
f tumor cells or TILs.
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and immunohistochemical variables in different cell sub-
sets of the tumor microenvironment in samples from
136 ESCC patients are summarized in Table 1. In the
present study, the patients were divided into two groups
(a high-level group and a low-level group) based on the
medians of immunohistochemical variable values in di-
verse cell subsets. High expression levels of MIF in
tumor cells were not correlated with clinicopathological
variables, whereas high expression levels of CXCR4 in
tumor cells were positively closely correlated with T sta-
tus (P = 0.045) and clinical stage (P = 0.044). Further-
more, the expression levels of MIF and CXCR4 in TILs
were not related to any of the clinicopathological param-
eters, including age, gender, WHO grade, T status, N sta-
tus and clinical stage.
Immunohistochemical variables in diverse cell subsets
and patient survival
Among the 136 patients with ESCC, the median survival
time was 25 months (range: 0 to 33 months). The cumula-
tive five-year OS rate and DFS rate of the patients in this
study were 29 and 31%, respectively (data not shown). The
statistical analysis showed a significant negative correl-
ation between DFS, OS and the expression levels ofTable 1 Association of the expression of MIF, CXCR4 and clin
Clinicopathologic
parameter




Pa High level expressio
of CXCR4 (%)
Age
≤62 (y) 71 35 (49.3%) 0.284 26 (36.6%)
>62 (y) 65 38 (58.5%) 21 (32.3%)
Gender
Female 25 11 (44.0%) 0.283 9 (36.0%)
Male 111 62 (55.9%) 38 (34.2%)
WHO grade
G1 40 27 (67.5%) 0.087 13 (32.5%)
G2 59 30 (50.8%) 19 (32.2%)
G3 37 16 (43.2%) 15 (40.5%)
T status
T1-2 44 22 (50.0%) 0.552 10 (22.7%)
T3-4 92 51 (55.4%) 37 (40.2%)
N status
N0 69 36 (52.2%) 0.721 20 (29.0%)
N1 67 37 (55.2%) 27 (40.3%)
Clinical stage
I-II 74 41 (55.4%) 0.659 20 (27.0%)
III-IV 62 32 (51.6%) 27 (43.5%)
Note: *P < 0.05, a, Pearson’s X2 test. b, Fisher’s X2 test.MIF in tumor cells and TILs and CXCR4 in tumor
cells (P < 0.05, Figure 2).
The univariate analysis demonstrated that high expres-
sion levels of MIF (P = 0.032 and P = 0.030) or CXCR4
(P = 0.030 and P = 0.028) in tumor cells were noticeably
correlated with reduced DFS and OS and that high ex-
pression level MIF (P = 0.023 and P = 0.044) in TILs
were also significantly associated with decreased DFS
and OS; however, the high expression of CXCR4 was
weakly correlated with improved DFS and OS (P > 0.05)
(Table 2). As expected, and as shown in Table 2, clinico-
pathological parameters such as gender, WHO grade,
nodal status and TNM stage are also of prognostic value.
Furthermore, we determined that, with the exception of
classical prognostic factors such as gender and WHO
grade, the expression of MIF or CXCR4 in tumor cells
and the MIF expression in TILs were independent pre-
dictors of DFS and OS according to the multivariate Cox
model analysis (Table 3).
The expression levels of MIF and CXCR4 in diverse cell
subsets and the survival of patients with metastatic/
recurrent ESCC
Among the 136 patients with ESCC, there were 67
(49.3%) patients with locoregional ESCC and 69icopathologic parameters in 136 patients with ESCC
Expression in TILs
n Pa High level
expression of
MIF (%)
Pa High level expression
of CXCR4 (%)
Pa
0.597 31 (43.7%) 0.122 38 (53.5%) 0.391
37 (56.9%) 30 (46.2%)
0.867 14 (56.0%) 0.507 17 (68.0%) 0.075b
54 (48.6%) 51 (45.9%)
0.669 22 (55.0%) 0.579 19 (47.5%) 0.448
30 (50.8%) 33 (55.9%)
16 (43.2%) 16 (43.2%)
0.045* 19 (43.2%) 0.271 24 (54.5%) 0.463
49 (53.3%) 44 (47.8%)
0.165 32 (46.4%) 0.391 37 (53.6%) 0.391
36 (53.7%) 31 (46.3%)
0.044* 37 (50.0%) 1.00 41 (55.4%) 0.168
31 (50.0%) 27 (43.5%)
A In tumor cells
B In TILs
Figure 2 Kaplan-Meier survival analysis in patients with ESCC. (A) Disease-free survival and overall survival curves for patients according to
the low and high expression levels of immunohistochemical variables in tumor cells. (B) Disease-free survival and overall survival curves for
patients according to the low and high expression levels of immunohistochemical variables in TILs.
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univariate analysis demonstrated that the high ex-
pression levels of MIF (P = 0.012 and P = 0.011) or
CXCR4 (P = 0.010 and P = 0.012) in tumor cellswere significantly correlated with poor DFS and OS
in patients with metastatic/recurrent ESCC (Figure 3)
but no association with locoregional ESCC (Data not
shown).
Table 2 Univariate analysis of DFS and OS in 136 patients with ESCC
Variables DFS (n=136) OS (n=136)
HR (95% CI) P HR (95% CI) P
Age, years (≤62/>62) 0.682 (0.462-1.005) 0.053 0.714 (0.483-1.054) 0.090
Gender (male/female) 0.452 (0.256-0.798) 0.006* 0.417 (0.232-0.747) 0.003*
WHO Grade (1/2/3) 1.362 (1.053-1.763) 0.019* 1.324 (1.023-1.715) 0.033*
Tumor (T) status (1-2/3-4) 1.569 (1.019-2.416) 0.041* 1.508 (0.976-2.332) 0.064
Nodal (N) status (0/1) 2.095 (1.415-3.101) <0.001* 1.998 (1.346-2.965) 0.001*
TNM stage (I-II/III-IV) 1.346 (1.110-1.633) 0.003* 1.318 (1.085-1.601) 0.005*
MIF in tumor cells (low/high) 1.518 (1.028-2.242) 0.036* 1.532 (1.034-2.269) 0.033*
CXCR4 in tumor cells (low/high) 1.537 (1.035-2.283) 0.033* 1.550 (1.041-2.307) 0.031*
MIF in lymphocytes (low/high) 1.548 (1.053-2.275) 0.026* 1.481 (1.003-2.185) 0.048*
CXCR4 in lymphocytes (low/high) 0.738 (0.501-1.085) 0.122 0.715 (0.485-1.055) 0.091
Note: * P < 0.05.
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CXCR4 in diverse cell populations and survivals of
patients
In the current study, Pearson’s correlation coefficient
and a linear regression analysis were applied to evaluate
the correlations between the expression levels of MIF
and CXCR4 in tumor cells and TILs. The MIF expres-
sion levels in tumor cells and in TILs were significantly
positively correlated with the CXCR4 expression levels
in tumor cells and in TILs (P = 0.009, R = 0.224 and
P = 0.026, R = 0.191, respectively), as shown in Figure 4A
and 4B. Furthermore, the patients with the double high
expression levels of MIF and CXCR4 in tumor cells had
the worst DFS and OS compared to the patients with
single high expression level of MIF or CXCR4 in tumor
cells or double low expression level of MIF and CXCR4
in tumor cells (P = 0.002 and P = 0.006, respectively,
Figure 4C and 4D). Furthermore, the combined expres-
sion of MIF and CXCR4 in tumor cells was an inde-
pendent predictive factor for DFS and OS according to
the multivariate Cox model analysis (Table 2).
Discussion
A serial of inflammatory cytokine and its receptor genes
overexpress in different cell subsets of tumor microenvi-
ronments, including tumor cells and immune cells, toTable 3 Multivariate Cox analyses for DFS and OS of 136 pati
Variables
MIF in Tumor cells (low/high) 1.
CXCR4 in Tumor cells (low/high) 1.
MIF in Lymphocytes (low/high) 1.
Combination of MIF and CXCR4 in tumor cells (low/mid/high) 1.
Note: The Cox proportional hazards regression model contained the significantly di
status and TNM stage. HR, hazard ratio; CI, confidence interval; * means P < 0.05.control the “cross talk” between tumor cells and im-
mune cells and impact on the disease progression and
clinical outcome of cancer patients [28]. MIF, a cytokine
overexpressed in tumor microenvironments plays a crit-
ical role in several inflammatory conditions, as well xas
in oncogenic transformation and tumor progression
[29-32]. CXCR4 is the receptor of stromal cell-derived
factor-1 (CXCL12/SDF-1α) and can also bind to MIF,
and takes an important role in tumor progression and
anti-tumor immunity. However, the association between
the expression levels of MIF and CXCR4 in diverse cell
populations of the tumor microenvironment and the
survival of cancer patients remains ambiguous. In this
context, we examined the expression pattern of MIF and
CXCR4 in different cell populations in tumor tissues
from 136 patients with ESCC, to determine the predict-
ive value of the MIF and CXCR4 expressions in different
cell populations within tumor microenvironment of
ESCC.
High MIF levels were found in the tumors and sera of
patients with different types of cancer, and MIF produc-
tion has been consistently associated with the aggressive-
ness and metastatic potential of human tumors [33-36].
Our results suggest that MIF could be expressed in the
cytoplasm of tumor cells and TILs (Figure 1). In the
present study, our results demonstrated for the first timeents with ESCC
DFS (n=136) OS (n=136)
HR (95% CI) p HR (95% CI) p
689 (1.132-2.521) 0.010* 1.619 (1.084-2.418) 0.018*
708 (1.126-2.591) 0.012* 1.612 (1.072-2.425) 0.022*
473 (0.999-2.172) 0.050* 1.523 (1.027-2.259) 0.037*
338 (1.064-1.683) 0.013* 1.263 (1.009-1.583) 0.042*
fferent factors in univariate analysis, including gender, WHO grade, T status, N
a b
c d
Figure 3 Kaplan-Meier survival analysis in patients with metastatic/recurrent ESCC. Disease-free survival and overall survival curves for
metastatic/recurrent ESCC patients with low and high expression levels of MIF in tumor cells (a and b). Disease-free survival and overall survival
curves for metastatic/recurrent ESCC patients with low and high expression levels of CXCR4 in tumor cells (c and d).
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nificantly and independently associated with poor DFS
and OS in patients with ESCC (Figure 2A), as well as
that high MIF expression in tumor cells is an adverse in-
dependent factor for DFS and OS in patients with meta-
static/recurrent ESCC (Figure 3). Many studies have
demonstrated that the biological function of MIF in
tumor cells is to promote the growth of tumor cells;
however, the expression of MIF in tumor tissues and
patients’ clinical outcomes differed for different types
of cancers [35,37-41]; our previous study showed that
the increased expression of MIF in TILs within tumor
microenvironments was correlated with improved out-
comes for patients with nasopharyngeal carcinoma
(NPC) [25]. Recent studies have indicated that MIF can
induce the generation and homing of Th17 cells to the
tumor microenvironments [25,42]; however, the function
and clinical relevance of Th17 cells in tumor microenvi-
ronments were conflicting in different cancers [43,44].
Therefore, we think that although the expression of MIF
in tumor cells is to promote the tumor cell growth as an
‘oncogenic gene’, the MIF expression in immune cells isassociate with intratumoral immune response; this may
explain the different impact of MIF expressions within
tumor microenvironments on the survival of patients in
different cancers.
CXCR4 promotes tumor progression at different levels
of malignancy, including tumor growth, angiogenesis,
metastatic dissemination, and homing in CXCL12-
enriched cellular niches in metastatic tissues [45-47].
CXCR4 expression is a prognostic marker in various
types of cancer, including acute myelogenous leukemia,
breast and colon carcinomas [48,49]. Our data revealed
that CXCR4 could be expressed in the nucleus, cyto-
plasm and cell membrane of tumor cells and TILs
(Figure 1). In the current study, CXCR4 expression
levels in tumor cells were positively associated with pri-
mary tumor invasion and clinical stage progression. Our
results were consistent with other researchers’ findings
regarding the biological functions of CXCR4 in malig-
nant cells; namely, CXCR4 promoted malignant cell
proliferation, anti-apoptosis and metastasis [45]. How-
ever, the expression of CXCR4 in tumor cells was sig-
nificantly associated with poor DFS and OS in patients
A B


































Figure 4 Correlation analysis between the MIF and CXCR4 expressions in different cell populations and survival curves for ESCC
patients according to their expression levels of MIF and CXCR4 in tumor cells. (A) The expression levels of MIF and CXCR4 in tumor cells
were significantly positively correlated (P = 0.009, R = 0.224). (B) The expression levels of MIF and CXCR4 in TILs were significantly positively
correlated (P = 0.026, R = 0.191). (C and D) Disease-free survival and overall survival curves for patients according to the combined low expression
level, single high and combined high expression level of MIF and CXCR4 in tumor cells and TILs.
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CXCR4 expression in TILs was associated with a
slightly improved DFS and OS (P = 0.122 and P = 0.091,
respectively) in the ESCC patients in our study (Figure 2
and Figure 3). Our results imply that CXCR4 has differ-
ent biological functions in tumor cells and lymphocytes
and that high CXCR4 expression in lymphocytes can
induce the homing of immune cells to tumor micro-
environments to improve the number of TILs and the
anti-tumor immunity of TILs in ESCC. Therefore, the
combination of CXCR4 expression in both tumor cells
and TILs was not associated with the survival of ESCC
patients in this study (data not shown), and other studies
on CXCR4 expression in tumor tissues and the clinical
outcomes of ESCC patients also have reported conflicting
results [50,51].Importantly, MIF and CXCR4 expression levels in tumor
cells and in TILs were positively associated (Figure 4). Our
results suggest that the expression levels of MIF and
CXCR4 were altered in the same way in different cell pop-
ulations in the tumor microenvironments of ESCC and
that the CXCR4 protein was a receptor response to MIF
signaling in both immune cells and tumor cells. Interest-
ingly, our results showed for the first time that the com-
bined expression of MIF and CXCR4 in tumor cells was
also an independent prognostic marker for ESCC patients
and was strongly associated with reduced survival (Figure 4
and Table 3).
Conclusions
The expression of tumor-derived cytokine MIF and its
receptor CXCR4 were significantly associated with
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http://www.translational-medicine.com/content/11/1/60poor survivals of patients with ESCC; and the MIF and
CXCR4 expression levels in tumor cells were independent
predictive factors of survivals in patients with ESCC, as
were the MIF expression level in TILs. Furthermore, the
expression levels of MIF and CXCR4 in tumor cells were
independent predictive factors for survivals in patients
with metastatic/recurrent ESCC. Interestingly, the MIF
and CXCR4 expression levels in tumor cells and in TILs
were positively correlated, and the combined expression of
MIF and CXCR4 in tumor cells was an adverse independ-
ent factor for survivals of ESCC patients. Therefore, the
protein levels of MIF and CXCR4 in diverse cell popula-
tions within the tumor microenvironment have different
clinically prognostic values in ESCC. Further studies are
required to confirm our results in a large number of pa-
tients with ESCC.Additional files
Additional file 1: Table S1. Clinical characteristics of 136 patients with
ESCC.
Additional file 2: Table S2. Descriptive statistics of
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